ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial | Fierce Biotech
Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter
Celiac disease vaccine clinical trial canceled — here's a local expert's response | PhillyVoice
Celiac Vaccine Trial Participant Shares Experience With Nexvax2 - Gluten-Free Living
Nexvax2 Setback Only One Aspect of Ongoing Scientific Discovery | BeyondCeliac.org
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Current and emerging therapies for coeliac disease | Nature Reviews Gastroenterology & Hepatology
Celiac Disease Vaccine Candidate Granted FDA Fast Track — Precision Vaccinations
Frontiers | A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease | Immunology
A Participant's Perspective on the Failure of the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Celiac Disease Drug Pipeline: Waiting for the Celiac Cure - Celiac and the Beast
Discontinuation of the Nexvax2 Phase 2 trial - Coeliac New Zealand
Nexvax2 Therapeutic Vaccine | Celiac Disease Foundation
ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Coeliac Disease - Wesley Medical Research
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
ImmusanT Publishes Positive Data from Phase 1 Trials of its Celiac Disease Drug Nexvax2 - Drug Discovery and Development
Celiac Disease Vaccine Candidate Nexvax2 Shows Promise — Precision Vaccinations
Novel Nondietary Therapies for Celiac Disease - Cellular and Molecular Gastroenterology and Hepatology
Frontiers | Vaccine Immunotherapy for Celiac Disease | Medicine
ImmusanT cans phase 2 celiac trial after interim efficacy review | Fierce Biotech
Nexvax2® Research Update - Coeliac New Zealand
A Journey Through the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com
